| News

Redesigning Healthcare - Das war die Future Health 2019

05.02.2019

In der Gesundheitslandschaft der Zukunft steht der Patient im Mittelpunkt. Das zeigte auch die Future Health 2019 in Basel, die Ende Januar 350 Gäste anzog. Unter dem Titel “Redesigning Healthcare” diskutierten über 20 Referentinnen und Referenten über das Gesundheitssystem der Zukunft.

Noch werde der Patient zu wenig einbezogen, sagte Stephan Sigrist vom Think Tank W.I.R.E. Viele Patientinnen und Patienten wünschten sich mehr Transparenz, Partizipation und Dialog bei der Behandlung und insgesamt eine individuellere Betreuung.

Eine weitere Herausforderung beim Umbau des Gesundheitssystems sind Probleme, die sich aus der Nutzung biomedizinischer Daten ergeben. Effy Vayena, Professorin an der Universität Zürich, erforscht die Ethik der personalisierten Medizin. Sie widmete sich in ihrer Keynote der Frage, wer Gesundheitsdaten sammeln und auswerten dürfe.

Start-ups des DayOne Accelerators an der Future Health

Dass es an Ideen für die Zukunft der Gesundheitsindustrie nicht mangelt, bewiesen die Start-ups, die an der Future Health ihre Geschäftsmodelle präsentierten: Das Start-up Advancience aus Basel ermöglicht es, psychische Erkrankungen und auch bereits erste Anzeichen dafür mit Hilfe einer Software zu diagnostizieren. Beim Spielen eines Videogames werden verschiedene Parameter der Gehirnfunktion gemessen. Der Patient müsse für die Messung keine persönlichen Daten preisgeben, erklärte CEO und Co-Founder Christian Vogler in seinem Pitch. Advancience entstand an der Universität Basel. Das Start-up gehört ausserdem zu den Finalisten des DayOne Accelerators.

Auch das DayOne Accelerator Start-up Noul präsentierte seine Lösung für ein grosses Problem: «Jedes Jahr sterben weltweit 450’000 Menschen an Malaria – 70 Prozent davon sind Kinder», sagte Chang Rok Yun, Director of Global Development bei Noul, an der FutureHealth Basel. Um die vor allem in Entwicklungsländern verbreitete Krankheit effektiver zu bekämpfen, hat Noul ein tragbares Gerät namens MiLab entwickelt, dass ohne Labor und Techniker und nur anhand einer Blutprobe selbständig Malaria diagnostizieren kann. In Zukunft soll MiLab auch weitere Infektionskrankheiten erkennen, so Chang.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest

Moderna driving forward production of vaccine from Basel

Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel is “probably the most productive life sciences location in the world”

Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area cantons publish joint economic report

The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.

Read More
Basel Area Business & Innovation, Innovation

Resistell receives high-level EU grant

Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.